Biggest News Aggregation in the World
📰 Beigene News

Page 24 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

EUSA Pharma (UK), Ltd.: BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma

BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA(dinutuximab beta) conditional approval
United States Rebecca Kerr Gabrielle Zhou Xiaobin Wu Carsten Thiel European Commission

Fierce Pharma Asia—Moderna-Samsung COVID vaccine pact; Astellas' 5-year plan; more Novo investment

Moderna enlisted Samsung Biologics to help with fill-finish of its mRNA COVID-19 vaccine. Astellas targeted $17 billion in fiscal 2025 sales in a new five-year plan. Novo Holdings co-led a $200 million financing round in a Singapore cell and gene therapy tech company. And more
National University Of Singapore Singapore General United States Inch On Gwangyoksi South Korea Sanofi Dengvaxia

Fierce Pharma Asia—BeiGene-Novartis PD-1 deal; Sinovac vaccine; Celltrion antibody COVID-19 data

Brazilian researchers first said Sinovac’s COVID-19 vaccine, CoronaVac, was 78% effective in a local phase 3 trial. But then, a few days ago, they released new data of just 50.4% efficacy. The gap was caused by the omission of “very mild” infections in the previous data. The misstep led to criticism of the trial organization, Brazil’s Butantan biomedical center, as well as suspicion about CoronaVac’s true efficacy. Turkey just authorized the shot for emergency use based on a reported...
United States Michael Goettler John Oyler Sinovac Biotech South Korea Pd 1 L1

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BeiGene announces Novartis collaboration on antibody

BeiGene announces Novartis collaboration on antibody By Liu Zhihua | chinadaily.com.cn | Updated: 2021-01-13 11:13 Share CLOSE Scientists discuss use of equipment at the central chemistry lab of BeiGene in Beijing in May 2017. [Photo provided to chinadaily.com.cn] China-based biotechnology company BeiGene Ltd held a media conference in Beijing on Tuesday to announce its collaboration and license agreement with Swiss pharmaceutical compa...
United States United Kingdom Johnv Oyler China National Medical Products Administration European Union Beigene Ltd

Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy

Message : Required fields (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhans move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharmas...
United States Derek Francis Susanne Schaffert Novartis Narasimhan Bristol Myers Squibb Michael Shields

RPT-UPDATE 1-Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy

* Novartis’s China foray follows Pfizer deal in September * Swiss drugmaker playing catch-up on cancer immunotherapy * Novartis CEO was previously tepid on Chinese assets Jan 12 (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd , the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhan’s move, which could bring $1.55 billion in milestone payments ...
United States Derek Francis Susanne Schaffert Novartis Narasimhan Bristol Myers Squibb Michael Shields

Twitter, Tesla, Realty Income, Cantel Medical: What to Watch When the Stock Market Opens Today

Here’s what we’re watching as markets kick into gear on Tuesday. — U.S. stock futures edged higher Tuesday, suggesting major indexes will resume their recent climb after a slide in technology shares weighed on markets at the start of the week. Read our full market wrap here. What’s Coming Up —Home builder KB Home will deliver its quarterly earnings report after markets close. —Live Q&A: Join WSJ chief economics correspondent Nick Timiraos for an interview with the St. Louis Fed’...
James Bullard Albertsons Cos Nick Timiraos Louis Fed Stock Market Today Wall Street
Source: wsj.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science